Furthermore, we found loss or mutation of TP53 and/or RB1 (hallmarks of SCLC) in the vast majority of PDX tumors; however, the mutations observed in genes previously associated with PARP inhibitor sensitivity were not predicted to be functionally relevant, nor were they significantly associated with talazoparib response in vivo (Figure 1H). The gene discussed is TP53; the disease is small cell lung carcinoma.